Q-omics provides the consensus-scored DHX15 profile across patient tissues and cancer cell-line models. DHX15 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DHX15 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, DHX15 protein abundance shows 27,478 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where DHX15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DHX15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DHX15 survival associations across molecular data types. DHX15 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DHX15 RNA expression–survival associations across cancer types. High DHX15 expression shows unfavorable associations in LGG, LIHC, CESC and ACC, but favorable associations in KIRC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DHX15 RNA expression.
This table summarizes DHX15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 10. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for DHX15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DHX15 shows lower tumor expression in THCA and higher tumor expression in COAD, STAD, LIHC, HNSC and LUAD. The COAD box plot shows higher DHX15 RNA expression in tumor versus normal tissue (log2 FC = +0.596, t-test p < 0.001).
This table shows molecular features associated with DHX15 in patient tissues and cancer cell lines. In patient samples, DHX15 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, DHX15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Leukemia.
